



Astec LifeSciences Ltd.

Date: 31st July, 2026

To,
BSE Limited
P. J. Towers, Dalal Street, Fort
Mumbai – 400 001

Ref.: BSE Scrip Code No. “533138”

To,
National Stock Exchange of India Limited
Exchange Plaza, Bandra - Kurla Complex,
Bandra (East), Mumbai-400 051

Ref.: “ASTEC”

Debt Segment NSE:
NCD-ASTEC-ISIN: INE563J08023

Sub.: Outcome of the Board Meeting

Pursuant to Regulations 30, 33 and 52(4) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”) read with Schedule III to the said Regulations, this is to inform you that the Board of Directors of the Company, at its Meeting held today, i.e., on **Friday, 31st July, 2026** (which commenced at 2.00 p.m. and concluded at 3.05 p.m.), *inter alia*, has approved / noted the following:

(a) Approval of the Unaudited Financial Results (Standalone & Consolidated) for the Quarter ended 30th June, 2026:

Upon recommendation of the Audit Committee, the Board of Directors has approved the Unaudited Financial Results (Standalone & Consolidated) as per Indian Accounting Standards (IND AS) for the Quarter ended 30th June, 2026 (enclosed herewith).

(b) Noting of the Limited Review Reports of the Statutory Auditors for the Quarter ended 30th June, 2026:

The Board of Directors took note of the Limited Review Reports of the Statutory Auditors on the Unaudited Financial Results (Standalone & Consolidated) for the Quarter ended 30th June, 2026 (enclosed herewith).

The Limited Review Reports of the Statutory Auditors are with unmodified opinion with respect to the Unaudited Financial Results (Standalone and Consolidated) of the Company for the Quarter ended 30th June, 2026.



Regd. Office :
“Godrej One”, 3rd Floor,
Pirojshanagar, Eastern Express Highway,
Vikhroli (East), Mumbai - 400079,
Maharashtra, India
Telephone No. : 022-25188010
Fax No. : 022-22618289
Email id : astecinfo@godrejastec.com
Website : www.godrejastec.com
CIN : L99999MH1994PLC076236



Astec LifeSciences Ltd.

Please take the above information on your records.

Thanking you,

Yours sincerely,

For Astec LifeSciences Limited

**Tejashree Pradhan
Company Secretary & Compliance Officer
(FCS 7167)**

Encl.: As above



Regd. Office :
"Godrej One", 3rd Floor,
Pirojshanagar, Eastern Express Highway,
Vikhroli (East), Mumbai - 400079,
Maharashtra, India
Telephone No. : 022-25188010
Fax No. : 022-22618289
Email id : astecinfo@godrejastec.com
Website : www.godrejastec.com
CIN : L99999MH1994PLC076236

Astec LifeSciences Limited

Corporate Identity Number : L99999MH1994PLC076236

Registered Office : Godrej One, 3rd Floor, Pirojshanagar, Eastern Express Highway, Vikhroli (East), Mumbai- 400079, Maharashtra

Website: www.godrejastec.com, Tel no.: 022-2519 5768, Fax no.: 022-2261 8289, Email id: astecinvestors@godrejastec.com

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2026

(Rs. in lakhs)

Standalone				Particulars	Consolidated			
Quarter Ended			Year Ended		Quarter Ended			Year Ended
30-Jun-26 (Unaudited)	31-Mar-26 (Refer Note 4)	30-Jun-25 (Unaudited)	31-Mar-26 (Audited)		30-Jun-26 (Unaudited)	31-Mar-26 (Refer Note 4)	30-Jun-25 (Unaudited)	31-Mar-26 (Audited)
				INCOME				
8,356.43	15,862.27	9,108.21	44,814.56	Revenue From Operations	8,356.43	15,862.26	9,108.21	44,814.56
70.85	261.41	48.66	498.87	Other Income	72.74	263.36	50.65	507.09
8,427.28	16,123.68	9,156.87	45,313.43	TOTAL INCOME	8,429.17	16,125.62	9,158.86	45,321.65
				EXPENSES				
7,632.28	7,127.45	5,940.62	27,045.00	Cost of materials consumed	7,632.28	7,127.45	5,940.62	27,045.01
(3,370.38)	3,906.16	447.77	2,796.44	Changes in inventories of finished goods and Work-in-progress	(3,370.38)	3,906.17	447.77	2,796.44
1,599.96	1,632.12	1,518.41	6,290.81	Employee benefits expense	1,599.96	1,632.12	1,518.41	6,290.81
773.99	793.33	1,104.90	3,456.76	Finance costs	773.18	792.22	1,104.38	3,452.89
1,108.62	1,178.82	1,151.02	4,499.34	Depreciation and amortisation expenses	1,106.77	1,176.97	1,149.41	4,492.18
2,560.73	2,280.29	2,299.79	9,132.84	Other expenses	2,561.18	2,280.70	2,300.02	9,134.90
10,305.20	16,918.17	12,462.51	53,221.19	TOTAL EXPENSES	10,302.99	16,915.63	12,460.61	53,212.23
(1,877.92)	(794.49)	(3,305.64)	(7,907.76)	LOSS BEFORE EXCEPTIONAL ITEMS & TAX	(1,873.82)	(790.01)	(3,301.75)	(7,890.58)
-	-	-	209.43	Exceptional items (Refer Note 3)	-	-	-	209.43
(1,877.92)	(794.49)	(3,305.64)	(8,117.19)	LOSS BEFORE TAX	(1,873.82)	(790.01)	(3,301.75)	(8,100.01)
(4.08)	(16.31)	-	(16.31)	Tax expense:	(3.09)	(15.31)	0.94	(12.39)
-	-	-	-	1. Current tax	0.98	0.99	1.06	4.00
(4.08)	(16.31)	-	(16.31)	2. Deferred tax expense / (income)	(4.07)	(16.30)	(0.12)	(16.39)
(1,873.84)	(778.18)	(3,305.64)	(8,100.88)	LOSS AFTER TAX FOR THE PERIOD/YEAR	(1,870.73)	(774.70)	(3,302.69)	(8,087.62)

Angad Mulhraj




(Rs. in lakhs)

Standalone				Particulars	Consolidated			
Quarter Ended			Year Ended		Quarter Ended			Year Ended
30-Jun-26 (Unaudited)	31-Mar-26 (Refer Note 4)	30-Jun-25 (Unaudited)	31-Mar-26 (Audited)		30-Jun-26 (Unaudited)	31-Mar-26 (Refer Note 4)	30-Jun-25 (Unaudited)	31-Mar-26 (Audited)
16.20	38.04	5.64	64.80	OTHER COMPREHENSIVE INCOME	16.20	38.04	5.64	64.80
(4.08)	(16.31)	-	(16.31)	(A) (i) Items that will not be reclassified to profit or loss	(4.08)	(16.31)	-	(16.31)
-	-	-	-	(ii) Income tax related to Items that will not be reclassified to profit or loss	(0.77)	(0.70)	(0.29)	(2.32)
-	-	-	-	(B) (i) Items that will be reclassified to profit or loss	-	-	-	-
				(ii) Income tax related to items that will be reclassified to profit or loss				
12.12	21.73	5.64	48.49	TOTAL OTHER COMPREHENSIVE INCOME FOR THE YEAR, NET OF INCOME TAX	11.35	21.03	5.35	46.17
(1,861.72)	(756.45)	(3,300.00)	(8,052.39)	TOTAL COMPREHENSIVE LOSS FOR THE YEAR	(1,859.38)	(753.67)	(3,297.34)	(8,041.45)
				Loss for the period attributable to:				
				a) Owners of the Company	(1,871.74)	(775.73)	(3,303.78)	(8,091.75)
				b) Non Controlling Interest	1.01	1.03	1.09	4.13
				Other Comprehensive Income attributable to:				
				a) Owners of the Company	11.35	21.03	5.35	46.17
				b) Non Controlling Interest	-	-	-	-
				Total Comprehensive Loss attributable to:				
				a) Owners of the Company	(1,860.39)	(754.70)	(3,298.43)	(8,045.58)
				b) Non Controlling Interest	1.01	1.03	1.09	4.13
2,228.28	2,228.22	1,961.17	2,228.22	Paid-up Equity share capital (Face Value Rs. 10 per share)	2,228.28	2,228.22	1,961.17	2,228.22
			36,758.42	Other Equity				36,832.36
				Earnings per equity share of Rs. 10 each (non-annualized)				
(8.41)	(3.49)	(16.86)	(37.83)	Basic (Rs.)	(8.40)	(3.48)	(16.85)	(37.79)
(8.41)	(3.49)	(16.85)	(37.83)	Diluted (Rs.)	(8.40)	(3.48)	(16.85)	(37.79)

Angela Mulhejkar

Astec Life Sciences Ltd.
Mumbai



Astec LifeSciences Limited
Corporate Identity Number : L99999MH1994PLC076236
Registered Office : Godrej One, 3rd Floor, Pirojshanagar, Eastern Express Highway, Vikhroli (East), Mumbai- 400079, Maharashtra
Website: www.godrejastec.com, Tel no.: 022-2519 5768, Fax no.: 022-2261 8289, Email id: astecinvestors@godrejastec.com
Additional disclosures as per Clause 52(4) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015


Standalone				Particulars	Consolidated			
Quarter Ended			Year ended		Quarter Ended			Year ended
30-Jun-26 (Unaudited)	31-Mar-26 (Refer Note 4)	30-Jun-25 (Unaudited)	31-Mar-26 (Audited)		30-Jun-26 (Unaudited)	31-Mar-26 (Refer Note 4)	30-Jun-25 (Unaudited)	31-Mar-26 (Audited)
0.83	0.88	0.78	0.88	Current Ratio (refer note 1)	0.83	0.89	0.78	0.89
37,128.05	38,986.64	20,112.25	38,986.64	Net Worth (in Rs. Lakh)	37,235.59	39,091.84	20,180.95	39,091.79
-	-	-	-	Outstanding redeemable preference shares (quantity and value)	-	-	-	-
(1,873.84)	(778.18)	(3,305.64)	(8,100.88)	Net profit/(loss) after tax (in Rs. Lakh)	(1,870.73)	(774.70)	(3,302.69)	(8,087.62)
(8.41)	(3.49)	(16.86)	(37.83)	Basic Earnings per share	(8.40)	(3.48)	(16.85)	(37.79)
(8.41)	(3.49)	(16.85)	(37.83)	Diluted Earnings per share	(8.40)	(3.48)	(16.85)	(37.79)
0.30	0.30	0.30	0.30	Capital Redemption Reserve (in Rs. Lakh)	0.30	0.30	0.30	0.30
0.99	1.15	2.96	1.15	Debt Equity ratio (refer note 1)	0.98	1.15	2.95	1.15
0.01	0.66	(0.21)	(0.01)	Debt Service Coverage Ratio (DSCR) (refer note 1)	0.01	0.66	(0.21)	(0.01)
0.03	1.50	(0.95)	(0.04)	Interest Service Coverage Ratio (ISCR) (refer note 1)	0.03	1.51	(0.95)	(0.04)
8.65	4.49	*	4.49	Long term debt to working capital (refer note 1)	7.93	4.31	*	4.31
-	-	-	-	Bad debts to Account receivable ratio (refer note 1)	-	-	-	-
0.73	0.74	0.62	0.74	Current liability ratio (refer note 1)	0.73	0.75	0.62	0.75
0.43	0.48	0.68	0.48	Total debts to total assets (refer note 1)	0.43	0.48	0.68	0.48
1.61	2.87	2.77	2.25	Debtors turnover (refer note 1)	1.61	2.87	2.77	2.25
2.15	4.02	2.33	3.01	Inventory turnover (refer note 1)	2.15	4.02	2.33	3.01
-0.79%	5.78%	-12.06%	-1.47%	Operating margin (%) (refer note 1)	-0.80%	5.77%	-12.06%	-1.48%
-22.42%	-4.91%	-36.29%	-18.08%	Net profit/(loss) margin (%) (refer note 1)	-22.39%	-4.88%	-36.26%	-18.05%

* Working Capital is negative

- 1 Pursuant to SEBI Operational Circular for Issue and Listing of Non-Convertible Securities, Securitised Debt Instruments, Security Receipts, Municipal Debt Securities and Commercial Paper dated August 10, 2021, the Company has listed Commercial Papers on National Stock Exchange (NSE).
The Company is rated by leading credit agency ICRA and India Ratings & Research. ICRA has assigned the rating "[ICRA] A1+" for its short term facilities (including commercial paper) and "[ICRA] AA-" for its long term facilities. India Ratings & Research has assigned "[IND] AA-" for its Non- Convertible Debentures (NCDs).
Formulae for computation of ratios:
Current ratio: Current assets / Current liabilities
Net Worth: Total equity
Debt Equity ratio: Total Debt / Shareholder's Equity
Debt Service Coverage Ratio: (Net Profit after taxes + Non-cash operating expenses like depreciation and other amortizations + Finance Costs + other adjustments like loss on sale of Fixed assets/Investment etc.) / (Interest & Lease Payments + Principal Repayments made during the year/period of long term debts)
Interest service coverage ratio: (Net Profit after taxes + Non-cash operating expenses like depreciation and other amortizations + Interest + other adjustments like loss on sale of Fixed assets/Investment etc.) / Finance Costs
Long term debt to working capital: (Non-current borrowings + Current maturities of long term debt) / (Current Assets - (Current liabilities - Current maturities of long term debt))
Bad debts to Account receivable ratio: Bad debts including provision for doubtful debts / Average Trade receivable.
Current liability ratio: (Current liabilities - Current maturities of Long term Debt) / Total liabilities
Total debts to total assets: Total borrowings / Total assets
Debtors turnover: Net Credit Sales / Average Trade Receivable (annualised)
Inventory turnover: Net Sales / Average Inventory (annualised)
Operating margin (%): Earnings before Interest, Tax & Depreciation & Amortisation less Other Income / Revenue from Operations
Net Profit/(Loss) margin(%): Profit/Loss after Tax (after exceptional items) / Revenue from Operations



Angel Muluheger




Notes:

- 1 The above Financial Results which are published in accordance with Regulations 33 and Regulations 52 (4) read with regulation 63 of the Securities and Exchange Board of India (Listing Obligations & Disclosure Requirements) Regulations, 2015 have been reviewed by the Audit Committee and have been approved by the Board of Directors at its Meeting held on Friday, July 31, 2026. The Financial Results are in accordance with the Indian Accounting Standards (Ind AS) as prescribed under section 133 of the Companies Act, 2013 ("Act"), read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 (including any amendment(s) / modification(s) / re-enactment(s) thereto). The Financial Results have been subjected to limited review by the Statutory Auditors and they have expressed an unmodified review conclusion.
- 2 The Group has only one reportable segment i.e. Agrochemicals as per Ind AS 108 "Operating Segments" specified under Section 133 of the Companies Act, 2013.
- 3 Impact of labour codes : On November 21, 2025, the Government of India notified the four Labour Codes - the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020 - consolidating 29 existing labour laws. Considering the materiality and regulatory-driven, non-recurring nature of this impact, the Group had presented incremental impact of Rs. 209.43 lakh under "Exceptional items" in the statement of profit and loss for the year ended March 31, 2026.
- 4 The figures for the quarter ended March 31, 2026 are the balancing figures between the audited figures in respect of the full financial year 2025-26 and the published year to date figures upto the third quarter of the financial year 2025-26. Also the figures upto the end of the third quarter had only been reviewed and not subjected to audit.

For Astec LifeSciences Limited




Arijit Mukherjee
Executive Director & Chief Operating Officer
DIN: 07334111
Place : Mumbai
Date : July 31, 2026



Limited Review Report on unaudited standalone financial results of Astec LifeSciences Limited for the quarter ended 30 June 2026 pursuant to Regulation 33 and Regulation 52(4) read with Regulation 63 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, as prescribed in Securities and Exchange Board of India operational circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10 August 2021, as amended

To the Board of Directors of Astec LifeSciences Limited

1. We have reviewed the accompanying Statement of unaudited standalone financial results of Astec LifeSciences Limited (hereinafter referred to as "the Company") for the quarter ended 30 June 2026 ("the Statement").
2. This Statement, which is the responsibility of the Company's management and approved by its Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 and Regulation 52(4) read with Regulation 63 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"), as prescribed in Securities and Exchange Board of India operational circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10 August 2021, as amended. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Attention is drawn to the fact that the figures for the three months ended 31 March 2026 as reported in the Statement are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.
5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 and Regulation 52(4) read with Regulation 63 of the Listing Regulations, as prescribed in Securities and Exchange Board of India operational circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10 August 2021, as amended, including the manner in which it is to be disclosed, or that it



Registered Office:

B S R & Co. LLP

Limited Review Report (Continued)


Astec LifeSciences Limited

contains any material misstatement.

For **B S R & Co. LLP**

Chartered Accountants

Firm's Registration No.: 101248W/W-100022



Rahul Choudhary

Partner

Mumbai

31 July 2026

Membership No.: 408408

UDIN:26408408CCDVRQ9714

Limited Review Report on unaudited consolidated financial results of Astec LifeSciences Limited for the quarter ended 30 June 2026 pursuant to Regulation 33 and Regulation 52(4) read with Regulation 63 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, as prescribed in Securities and Exchange Board of India operational circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10 August 2021, as amended

To the Board of Directors of Astec LifeSciences Limited

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Astec LifeSciences Limited (hereinafter referred to as “the Parent”), and its subsidiaries (the Parent and its subsidiaries together referred to as “the Group”) for the quarter ended 30 June 2026 (“the Statement”), being submitted by the Parent pursuant to the requirements of Regulation 33 and Regulation 52(4) read with Regulation 63 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (“Listing Regulations”), as prescribed in Securities and Exchange Board of India operational circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10 August 2021, as amended.
2. This Statement, which is the responsibility of the Parent’s management and approved by the Parent’s Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 “*Interim Financial Reporting*” (“Ind AS 34”), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 and Regulation 52(4) read with Regulation 63 of the Listing Regulations, as prescribed in Securities and Exchange Board of India operational circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10 August 2021, as amended. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 “*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*”, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the entities mentioned in Annexure I to the Statement.
5. Attention is drawn to the fact that the figures for the three months ended 31 March 2026 as reported in the Statement are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.



Limited Review Report (Continued)

Astec LifeSciences Limited

6. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review report of the other auditor referred to in paragraph 7 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 and Regulation 52(4) read with Regulation 63 of the Listing Regulations, as prescribed in Securities and Exchange Board of India operational circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10 August 2021, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
7. We did not review the interim financial information of One Subsidiary included in the Statement, whose interim financial information reflects total revenues (before consolidation adjustments) of Rs. 4.58 lakhs , total net profit after tax (before consolidation adjustments) and total comprehensive income (before consolidation adjustments) of Rs. 2.93 lakhs, for the quarter ended 30 June 2026, as considered in the Statement. These interim financial information has been reviewed by other auditor whose report has been furnished to us by the Parent's management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of this subsidiary, is based solely on the report of the other auditor and the procedures performed by us as stated in paragraph 3 above.

Our conclusion is not modified in respect of this matter.


8. The Statement includes the interim financial information of One Subsidiary which has not been reviewed, whose interim financial information reflects total revenues (before consolidation adjustments) of Rs. Nil , total net profit after tax (before consolidation adjustments) and total comprehensive income (before consolidation adjustments) of Rs. Nil, for the quarter ended 30 June 2026, as considered in the Statement. According to the information and explanations given to us by the Parent's management, these interim financial information are not material to the Group.

Our conclusion is not modified in respect of this matter.

For B S R & Co. LLP

Chartered Accountants

Firm's Registration No.:101248W/W-100022



Rahul Choudhary

Partner

Mumbai

31 July 2026

Membership No.: 408408

UDIN:26408408PGVPZX8735

Limited Review Report (Continued)

Astec LifeSciences Limited

Annexure I

List of entities included in unaudited consolidated financial results.

Sr. No	Name of component	Relationship
1	Astec LifeSciences Limited	Holding Company
2	Behram Chemicals Private Limited	Subsidiary Company
3	Comercializadora Agricola Agroastrachem Cia Ltda	Subsidiary Company

